title: Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.
abstract: Meningococcal disease caused by N. meningitidis serogroup B (MenB) has been endemic in Brazil since 1997. In this study, we determined the prevalence of serosubtypes of MenB isolated in 10 Brazilian states and the Federal District during 1997 and 1998 and investigated the extent of PorA VR sequence variation among the most prevalent serosubtypes to evaluate the possible use of an outer membrane vesicle (OMV)-, PorA-based vaccine to prevent meningococcal disease in Brazil. During this period, a total of 8,932 cases of meningococcal disease were reported. Only 42% (n = 3,751) of the reported cases were laboratory confirmed, and about 60% (n = 2,255) of those were identified as MenB. Among 1,297 MenB strains selected for this study, the most prevalent serosubtypes were P1.19,15 (66%), P1.7,1 (11%), and P1.7,16 (4%). PorA VR typing showed that 91% of the P1.19,15 strains analyzed had VR1 and VR2 sequences identical to those of the prototype strain. No sequence variation was detected among the 40 strains representing all isolated MenB P1.7,16 strains in the three southern states, where this serosubtype accounts for 75% of the serosubtypes identified. Similarly, all P1.7,1 strains were identified by PorA typing as P1.7-1,1. Although further improvements in the reporting of cases and collection of strains in Brazil are needed, our data suggest that a trivalent OMV-based vaccine prepared with PorA types P1.19,15, P1.7-1,1, and P1.7,16 may be appropriate to control serogroup B meningococcal disease in most of the Brazilian states.
authors.affiliation: Meningitis and Special Pathogens Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. cls9@cdc.gov
authors.forename: C T
authors.initials: CT
authors.lastname: Sacchi
authors.forename: A P
authors.initials: AP
authors.lastname: Lemos
authors.forename: T
authors.initials: T
authors.lastname: Popovic
authors.forename: J C
authors.initials: JC
authors.lastname: De Morais
authors.forename: A M
authors.initials: AM
authors.lastname: Whitney
authors.forename: C E
authors.initials: CE
authors.lastname: Melles
authors.forename: L M
authors.initials: LM
authors.lastname: Brondi
authors.forename: L M
authors.initials: LM
authors.lastname: Monteiro
authors.forename: M V
authors.initials: MV
authors.lastname: Paiva
authors.forename: C A
authors.initials: CA
authors.lastname: Solari
authors.forename: L W
authors.initials: LW
authors.lastname: Mayer
mesh_terms: D001938:Brazil / Q000453:epidemiology; D014644:Genetic Variation; D006801:Humans; D008589:Meningococcal Infections / Q000453:epidemiology / Q000382:microbiology* / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000276:immunology; D008969:Molecular Sequence Data; D009345:Neisseria meningitidis / Q000145:classification* / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D018272:Porins / Q000145:classification* / Q000235:genetics* / Q000276:immunology; D015995:Prevalence; D012703:Serotyping
chemical_list: D022401:Meningococcal Vaccines; D018272:Porins; C057699:porin protein, Neisseria